Journal of Literature Pharmacy Sciences

Herbal Preparations Used Against Fatty Liver Disease: Systematic Review
Karaciğer Yağlanmasına Karşı Kullanılan Bitkisel Preparatlar: Sistematik Derleme
Ayşe Esra KARADAĞa,b, Fatih DEMİRCİ c,d
aDepartment of Pharmacognosy, İstanbul Medipol University Faculty of Pharmacy, İstanbul, Türkiye
bDepartment of Pharmacognosy, İstanbul Medipol University Faculty of Pharmacy, İstanbul, Türkiye
cDepartment of Pharmacognosy, Anadolu University Faculty of Pharmacy, Eskişehir, Türkiye
dDepartment of Pharmacognosy, Eastern Mediterranean University Faculty of Pharmacy, Famagusta, Turkish Republic of Northern Cyprus
J Lit Pharm Sci. 2022;11(3):177-88
doi: 10.5336/pharmsci.2022-91392
Article Language: EN
Full Text
ABSTRACT
The fatty liver disease is defined as more than 5% of liver histiocytes filled with fatty vacuoles, depending on diet and independent of alcohol consumption. As it is known, fatty liver and related disorders are common, but still have no effective treatment. It is one of the important health problems in developed countries, associated with social and economic problems. Non-alcoholic fatty liver disease (NAFLD) is among the most common chronic metabolic disorders. It was observed that the prevalence of NAFLD has increased significantly worldwide in recent years. With advancing obesity epidemics, NAFLD has become the most common cause of chronic liver disease both in adults and children. Therefore, the clinical and economic burden of the disease is remarkable and increasing within the health system. While fatty liver is a metabolic disorder that has no definite drug treatment today, there are some traditional preparations used for this purpose as ethnobotanically. According to ethnobotanical studies in the current literature associated to liver diseases; various in vitro, in vivo, or clinical experimental studies were reported with successful results. Thus, in this present review, studies on natural sourced raw materials, herbal formulations related to liver diseases, especially fatty liver, obesity, hyperlipidemia were compiled mainly from ethnobotanical origin.

Keywords: Fatty liver; extract; herbal drug; natural product
ÖZET
Beslenmeye bağlı, alkol tüketiminden bağımsız karaciğer histiositlerinin %5?ten fazlasının yağ vakuolleriyle dolu olması ?yağlı karaciğer hastalığı? olarak tanımlanmaktadır. Bilindiği üzere karaciğer yağlanması ve karaciğer yağlanmasına bağlı rahatsızlıklar sık görülen ancak günümüzde kanıtlanmış etkin bir tedavisi olmayan metabolik rahatsızlıklardır. Ülkemizde de önemli sağlık sorunlarının başında gelmekte olup, sosyal ve ekonomik problemleri beraberinde getirmektedir. Nonalkolik yağlı karaciğer hastalığı, gelişmiş ülkelerde en yaygın kronik metabolik rahatsızlıklar arasındadır. Son yıllarda alkole bağlı olmayan yağlı karaciğer hastalığı prevalansının dünya genelinde önemli bir şekilde arttığı gözlenmiştir. İlerleyen obezite salgınları ile nonalkolik yağlı karaciğer hastalığı, erişkinlerde ve çocuklarda kronik karaciğer hastalığının en yaygın nedeni hâline gelmiştir. Bu nedenle yağlı karaciğer hastalığının klinik ve ekonomik yükü dikkate değerdir. Karaciğer yağlanması, günümüzde kesin bir ilaç tedavisi olmayan bir metabolik rahatsızlık iken, halk arasında bu amaçla kullanılan bazı geleneksel preparatlar mevcuttur. Karaciğer rahatsızlıklarında bitkiler etnobotanik çalışmalarda yer almış; çeşitli in vitro, in vivo veya klinik deneysel araştırmalarda yer almış olup, başarılı sonuçlar alınmıştır. Bu derlemede, bilhassa karaciğer yağlanması, obezite, hiperlipidemi başta olmak üzere karaciğer rahatsızlıkları ile ilişkili bitkiler, bitkisel formülasyonlar ve bitkilerden elde edilen doğal kaynaklı ham maddeler ile yapılan çalışmalar listelenmiştir. Gerek halk arasında kullanımları içeren, gerek deneysel çalışmaları (in vivo ve klinik çalışmalar) içeren makaleler derlenmiş ve özetlenmiştir.

Anahtar Kelimeler: Karaciğer yağlanması; ekstre; bitkisel ilaç; doğal ürün
REFERENCES:
  1. Seitz HK, Bataller R, Cortez-Pinto H, Gao B, Gual A, Lackner C, et al. Alcoholic liver disease. Nat Rev Dis Primers. 2018;4(1):16. Erratum in: Nat Rev Dis Primers. 2018;4(1):18. [Crossref]  [PubMed] 
  2. Kaya E, Yılmaz Y. Non-alcoholic fatty liver disease: A growing public health problem in Turkey. Turk J Gastroenterol. 2019;30(10):865-71. [Crossref]  [PubMed]  [PMC] 
  3. Amirkalali B, Poustchi H, Keyvani H, Khansari MR, Ajdarkosh H, Maadi M, et al. Prevalence of non-alcoholic fatty liver disease and its predictors in north of Iran. Iran J Public Health. 2014;43(9):1275-83. [PubMed]  [PMC] 
  4. Naderian M, Ebrahimi H, Sohrabpour AA. Prevalence of nonalcoholic fatty liver disease in the middle eastern area: What is the exact estimation? Hepatology. 2016;64(4):1390-1. [Crossref]  [PubMed] 
  5. Yan T, Yan N, Wang P, Xia Y, Hao H, Wang G, et al. Herbal drug discovery for the treatment of nonalcoholic fatty liver disease. Acta Pharm Sin B. 2020;10(1):3-18. [Crossref]  [PubMed]  [PMC] 
  6. Sohn EH, Kim T, Jeong YJ, Han HS, Lea Y, Cho YM, et al. Triglyceride control effect of Agrimonia eupatoria L. in oleic acid induced NAFLD-HepG2 model. Korean J Plant Resour. 2015;28(5):635-40. [Crossref] 
  7. Mohamadi N, Sharififar F, Koohpayeh A, Daneshpajouh M. Traditional and ethnobotanical uses of medicinal plants by ancient populations in Khabr and Rouchon of Iran. J Appl Pharm Sci. 2015;5(11):101-7. [Crossref] 
  8. Delfan B, Bahmani M, Kazemeini H, Zargaran A, Kopaei MR, Samani MA, et al. Identification of effective medicinal plants for hyperlipidemia: an ethnobotanical study in Lorestan Province, West of Iran. Tradit Integr Med. 2016;1(1):28-34. [Link] 
  9. Jiang G, Ramachandraiah K, Murtaza MA, Wang L, Li S, Ameer K. Synergistic effects of black ginseng and aged garlic extracts for the amelioration of nonalcoholic fatty liver disease (NAFLD) in mice. Food Sci Nutr. 2021;9(6):3091-9. [Crossref]  [PubMed]  [PMC] 
  10. Soleimani D, Paknahad Z, Askari G, Iraj B, Feizi A. Effect of garlic powder consumption on body composition in patients with nonalcoholic fatty liver disease: A randomized, double-blind, placebo-controlled trial. Adv Biomed Res. 2016;5:2. [Crossref]  [PubMed]  [PMC] 
  11. Moradi R, Hajialiani M, Salmani S, Almasi M, Zangeneh A, Zangeneh MM. Effect of aqueous extract of Allium saralicum R.M. Fritsch on fatty liver induced by high-fat diet in Wistar rats. Comp Clin Path. 2019;28(5):1205-11. [Crossref] 
  12. Hong X, Tang H, Wu L, Li L. Protective effects of the Alisma orientalis extract on the experimental nonalcoholic fatty liver disease. J Pharm Pharmacol. 2006;58(10):1391-8. [Crossref]  [PubMed] 
  13. Taheri S, Zarei A, Changizi Ashtiyani S, Rezaei A, Zaheiri S. Evaluation of the effects of hydroalcoholic extract of Berberis vulgaris root on the activity of liver enzymes in male hypercholesterolemic rats. Avicenna J Phytomed. 2012;2(3):153-61. [PubMed]  [PMC] 
  14. Yuan X, Wang J, Tang X, Li Y, Xia P, Gao X. Berberine ameliorates nonalcoholic fatty liver disease by a global modulation of hepatic mRNA and lncRNA expression profiles. J Transl Med. 2015;13:24. [Crossref]  [PubMed]  [PMC] 
  15. Yan HM, Xia MF, Wang Y, Chang XX, Yao XZ, Rao SX, et al. Efficacy of berberine in patients with non-alcoholic fatty liver disease. PLoS One. 2015;10(8):e0134172. [Crossref]  [PubMed]  [PMC] 
  16. Quan HY, Kim DY, Kim SJ, Jo HK, Kim GW, Chung SH. Betulinic acid alleviates non-alcoholic fatty liver by inhibiting SREBP1 activity via the AMPK-mTOR-SREBP signaling pathway. Biochem Pharmacol. 2013;85(9):1330-40. [Crossref]  [PubMed] 
  17. Pezeshki A, Safi S, Feizi A, Askari G, Karami F. The effect of green tea extract supplementation on liver enzymes in patients with nonalcoholic fatty liver disease. Int J Prev Med. 2016;7:28. [Crossref]  [PubMed]  [PMC] 
  18. Kuzu N, Bahcecioglu IH, Dagli AF, Ozercan IH, Ustündag B, Sahin K. Epigallocatechin gallate attenuates experimental non-alcoholic steatohepatitis induced by high fat diet. J Gastroenterol Hepatol. 2008;23(8 Pt 2):e465-70. [Crossref]  [PubMed] 
  19. Khavasi N, Somi M, Khadem E, Ayati MH, Torbati M, Fazljou SMB. Daily consumption of the capparis spinosa reduces some atherogenic indices in patients with non-alcoholic fatty liver disease: a randomized, double-blind, clinical trial. Iran Red Crescent Med J. 2018;20(6). [Crossref] 
  20. Ajayi T, Moody J. Ethnobotanical survey of plants used in the management of obesity in Ibadan South-western Nigeria. Nig J Pharm Res. 2018;1:22-31. [Link] 
  21. Heredia-Díaz Y, García-Díaz J, López-González T, Chil-Nu-ez I, Arias-Ramos D, Escalona-Arranz JC, et al. An ethnobotanical survey of medicinal plants used by inhabitants of Holguín, Eastern Region, Cuba. Boletín Latinoamericano y Del Caribe de Plantas Medicinales y Aromáticas. 2018;17(2):160-96. [Link] 
  22. Meng Y, Liu Y, Fang N, Guo Y. Hepatoprotective effects of Cassia semen ethanol extract on non-alcoholic fatty liver disease in experimental rat. Pharm Biol. 2019;57(1):98-104. [Crossref]  [PubMed]  [PMC] 
  23. Mei L, Tang Y, Li M, Yang P, Liu Z, Yuan J, et al. Co-administration of cholesterol-lowering probiotics and anthraquinone from cassia obtusifolia L. ameliorate non-alcoholic fatty liver. PLoS One. 2015;10(9):e0138078. [Crossref]  [PubMed]  [PMC] 
  24. Cui Y, Wang X, Xue J, Liu J, Xie M. Chrysanthemum morifolium extract attenuates high-fat milk-induced fatty liver through peroxisome proliferator-activated receptor α-mediated mechanism in mice. Nutr Res. 2014;34(3):268-75. [Crossref]  [PubMed] 
  25. Bahmani M, Shahinfard N, Rafieian-Kopaei M, Saki K, Shahsavari S, Taherikalani M, et al. Chicory: A review on ethnobotanical effects of Cichorium intybus L. Journal of Chemical and Pharmaceutical Sciences. 2015;8(4):672-82. [Link] 
  26. Mohammadifar M, Taghizadeh M, Abed A, Soltani A, Tamtaji O, Khamechian T, et al. Effect of Ziziphus jujuba Mill., Cichorium intybus L. and Silybum marianum (L.) Gaertn. Combination Extract on Non-alcoholic Fatty Liver Disease in Rats. J Med Plants. 2019;18(72):133-42. [Crossref] 
  27. Faraji S, Daneghian S, Alizadeh M. Persian medicine effects of chicory (Cichorium intybus L.) on nonalcoholic fatty liver disease. Persian Med. 2020;5(6):476. [Crossref] 
  28. Ziamajidi N, Khaghani S, Hassanzadeh G, Vardasbi S, Ahmadian S, Nowrouzi A, et al. Amelioration by chicory seed extract of diabetes- and oleic acid-induced non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH) via modulation of PPARα and SREBP-1. Food Chem Toxicol. 2013;58:198-209. [Crossref]  [PubMed] 
  29. Askari F, Rashidkhani B, Hekmatdoost A. Cinnamon may have therapeutic benefits on lipid profile, liver enzymes, insulin resistance, and high-sensitivity C-reactive protein in nonalcoholic fatty liver disease patients. Nutr Res. 2014;34(2):143-8. [Crossref]  [PubMed] 
  30. Han HY, Lee SK, Choi BK, Lee DR, Lee HJ, Kim TW. Preventive effect of citrus aurantium peel extract on high-fat diet-induced non-alcoholic fatty liver in mice. Biol Pharm Bull. 2019;42(2):255-60. [Crossref]  [PubMed] 
  31. Al Humayed S. Protective and therapeutic effects of Crataegus aronia in non-alcoholic fatty liver disease. Archives of Physiology and Biochemistry. 2017;123(1):23-30. [Crossref]  [PubMed] 
  32. Li Z, Xu J, Zheng P, Xing L, Shen H, Yang L, et al. Hawthorn leaf flavonoids alleviate nonalcoholic fatty liver disease by enhancing the adiponectin/AMPK pathway. Int J Clin Exp Med. 2015;8(10):17295-307. [PubMed]  [PMC] 
  33. Mashmoul M, Azlan A, Mohtarrudin N, Mohd Yusof BN, Khaza'ai H, Khoo HE, et al. Protective effects of saffron extract and crocin supplementation on fatty liver tissue of high-fat diet-induced obese rats. BMC Complement Altern Med. 2016;16(1):401. [Crossref]  [PubMed]  [PMC] 
  34. Parsi A, Torkashvand M, Hajiani E, Rahimlou M, Sadeghi N. The effects of Crocus sativus extract on serum lipid profile and liver enzymes in patients with non-alcoholic fatty liver disease: A randomized placebo-controlled study. Obes Med. 2020;17:100165. [Crossref] 
  35. Sangsefidi ZS, Yarhosseini F, Hosseinzadeh M, Ranjbar A, Akhondi-Meybodi M, Fallahzadeh H, et al. The effect of (Cornus mas L.) fruit extract on liver function among patients with nonalcoholic fatty liver: A double-blind randomized clinical trial. Phytother Res. 2021;35(9):5259-68. [Crossref]  [PubMed] 
  36. Cicero AFG, Colletti A, Bellentani S. Nutraceutical approach to non-alcoholic fatty liver disease (NAFLD): the available clinical evidence. Nutrients. 2018;10(9):1153. [Crossref]  [PubMed]  [PMC] 
  37. Leclercq IA, Farrell GC, Sempoux C, dela Pe-a A, Horsmans Y. Curcumin inhibits NF-kappaB activation and reduces the severity of experimental steatohepatitis in mice. J Hepatol. 2004;41(6):926-34. [Crossref]  [PubMed] 
  38. Rajabi M, Kalvandi R, Kahramfar Z, Cheleh TC. Investigation of the effect of artichoke (Cynara Scolymus L.) on characteristics of the fatty liver. Artic Complement Med J. 2020;10(2):134-47. [Crossref] 
  39. Kundu BB, Vanni K, Farheen A, Jha P, Pandey DK, Kumar V. Dioscorea bulbifera L. (Dioscoreaceae): a review of its ethnobotany, pharmacology and conservation needs. South African J Bot. 2021;140:365-74. [Crossref] 
  40. Wang T, Choi RC, Li J, Bi CW, Ran W, Chen X, et al. Trillin, a steroidal saponin isolated from the rhizomes of Dioscorea nipponica, exerts protective effects against hyperlipidemia and oxidative stress. J Ethnopharmacol. 2012;139(1):214-20. [Crossref]  [PubMed] 
  41. Liu M, Xu L, Yin L, Qi Y, Xu Y, Han X, et al. Potent effects of dioscin against obesity in mice. Sci Rep. 2015;5:7973. Erratum in: Sci Rep. 2015;5:12183. Erratum in: Sci Rep. 2020;10(1):18382. [Crossref]  [PubMed]  [PMC] 
  42. Susutlertpanya W, Werawatganon D, Siriviriyakul P, Klaikeaw N. Genistein attenuates nonalcoholic steatohepatitis and increases hepatic PPARγ in a rat model. Evid Based Complement Alternat Med. 2015;2015:509057. [Crossref]  [PubMed]  [PMC] 
  43. Lee JH, Felipe P, Yang YH, Kim MY, Kwon OY, Sok DE, et al. Effects of dietary supplementation with red-pigmented leafy lettuce (Lactuca sativa) on lipid profiles and antioxidant status in C57BL/6J mice fed a high-fat high-cholesterol diet. Br J Nutr. 2009;101(8):1246-54. [Crossref]  [PubMed] 
  44. Hosseini SMR, Razmgah GRG, Nematy M, Esmaily H, Yousefi M, Kamalinejad M, et al. Efficacy of black seed (Nigella sativa) and lemon balm (Melissa officinalis) on non-alcoholic fatty liver disease: A randomized controlled clinical trial. Iran Red Crescent Med J. 2018;20(3):e59183. [Crossref] 
  45. Ann JY, Eo H, Lim Y. Mulberry leaves (Morus alba L.) ameliorate obesity-induced hepatic lipogenesis, fibrosis, and oxidative stress in high-fat diet-fed mice. Genes Nutr. 2015;10(6):46. [Crossref]  [PubMed]  [PMC] 
  46. Yang X, Yang L, Zheng H. Hypolipidemic and antioxidant effects of mulberry (Morus alba L.) fruit in hyperlipidaemia rats. Food Chem Toxicol. 2010;48(8-9):2374-9. [Crossref]  [PubMed] 
  47. Xu J, Wang X, Cao K, Dong Z, Feng Z, Liu J. Combination of β-glucan and Morus alba L. Leaf Extract Promotes Metabolic Benefits in Mice Fed a High-Fat Diet. Nutrients. 2017;9(10):1110. [Crossref]  [PubMed]  [PMC] 
  48. Zhao W, Song F, Hu D, Chen H, Zhai Q, Lu W, et al. The protective effect of myristica fragrans houtt. Extracts against obesity and inflammation by regulating free fatty acids metabolism in nonalcoholic fatty liver disease. Nutrients. 2020;12(9):2507. [Crossref]  [PubMed]  [PMC] 
  49. Wani FA, Albahrawy AZ, Rahiman S. Hypolipidemic activity of olive oil (Olea europaea) against high fat diet-induced nonalcoholic fatty liver disease (NAFLD) in mice. Open J Pathol. 2015;5(3):73-83. [Crossref] 
  50. Dhibi M, Brahmi F, Mnari A, Houas Z, Chargui I, Bchir L, et al. The intake of high fat diet with different trans fatty acid levels differentially induces oxidative stress and non alcoholic fatty liver disease (NAFLD) in rats. Nutr Metab (Lond). 2011;8(1):65. [Crossref]  [PubMed]  [PMC] 
  51. Nigam P, Bhatt S, Misra A, Chadha DS, Vaidya M, Dasgupta J, et al. Effect of a 6-month intervention with cooking oils containing a high concentration of monounsaturated fatty acids (olive and canola oils) compared with control oil in male Asian Indians with nonalcoholic fatty liver disease. Diabetes Technol Ther. 2014;16(4):255-61. [Crossref]  [PubMed] 
  52. Shen L, Xiong Y, Wang DQ, Howles P, Basford JE, Wang J, et al. Ginsenoside Rb1 reduces fatty liver by activating AMP-activated protein kinase in obese rats. J Lipid Res. 2013;54(5):1430-8. [Crossref]  [PubMed]  [PMC] 
  53. Ahmad R, Almubayedh H, Ahmad N, Naqvi AA, Riaz M. Ethnobotany, ethnopharmacology, phytochemistry, biological activities and toxicity of Pistacia chinensis subsp. integerrima: A comprehensive review. Phytother Res. 2020;34(11):2793-819. [Crossref]  [PubMed] 
  54. Sirichaiwetchakoon K, Lowe GM, Kupittayanant S, Churproong S, Eumkeb G. Pluchea indica (L.) Less. Tea ameliorates hyperglycemia, dyslipidemia, and obesity in high fat diet-fed mice. Evid Based Complement Alternat Med. 2020;2020:8746137. [Crossref]  [PubMed]  [PMC] 
  55. Amiri H, Fakour S, Akradi L. Biochemical and histopathological study on preventive effects of Punica granatum L. extract on fatty liver disease in the rats receiving high fat diet. Sci J Kurdistan Univ Med Sci. 2018;23(3):45-55. [Link] 
  56. Liu YL, Lin LC, Tung YT, Ho ST, Chen YL, Lin CC, et al. Rhododendron oldhamii leaf extract improves fatty liver syndrome by increasing lipid oxidation and decreasing the lipogenesis pathway in mice. Int J Med Sci. 2017;14(9):862-70. [Crossref]  [PubMed]  [PMC] 
  57. Wu Z, Zhang Y, Gong X, Cheng G, Pu S, Cai S. The preventive effect of phenolic-rich extracts from Chinese sumac fruits against nonalcoholic fatty liver disease in rats induced by a high-fat diet. Food Funct. 2020;11(1):799-812. [Crossref]  [PubMed] 
  58. Davoodi I, Rahimi R, Abdollahi M, Farzaei F, Farzaei MH, Memariani Z, et al. Promising effect of Rosa damascena extract on high-fat diet-induced nonalcoholic fatty liver. J Tradit Complement Med. 2017;7(4):508-14. [Crossref]  [PubMed]  [PMC] 
  59. Abenavoli L, Aviello G, Capasso R, Milic N, Capasso F. Milk thistle for treatment of nonalcoholic fatty liver disease. Hepat Mon. 2011;11(3):173-7. [Link] 
  60. Wirngo FE, Lambert MN, Jeppesen PB. The physiological effects of dandelion (Taraxacum Officinale) in type 2 diabetes. Rev Diabet Stud. 2016;13(2-3):113-31. [Crossref]  [PubMed]  [PMC] 
  61. Mahboubi M, Mahboubi M. Hepatoprotection by dandelion (Taraxacum officinale) and mechanisms. Asian Pac J Trop Biomed. 2020;10(1):1-10. [Crossref] 
  62. Davaatseren M, Hur HJ, Yang HJ, Hwang JT, Park JH, Kim HJ, et al. Taraxacum official (dandelion) leaf extract alleviates high-fat diet-induced nonalcoholic fatty liver. Food Chem Toxicol. 2013;58:30-6. [Crossref]  [PubMed] 
  63. Siew YY, Zareisedehizadeh S, Seetoh WG, Neo SY, Tan CH, Koh HL. Ethnobotanical survey of usage of fresh medicinal plants in Singapore. J Ethnopharmacol. 2014;155(3):1450-66. [Crossref]  [PubMed] 
  64. Im JY, Ki HH, Xin M, Kwon SU, Kim YH, Kim DK, et al. Anti-obesity effect of Triticum aestivum sprout extract in high-fat-diet-induced obese mice. Biosci Biotechnol Biochem. 2015;79(7):1133-40. Erratum in: Biosci Biotechnol Biochem. 2016;80(3):619. [Crossref]  [PubMed] 
  65. Oh HS, Cho W, Tak SB, Kim S, Hong SP, Kim SO. Triticum aestivum ethanolic extract improves non-alcoholic fatty liver disease in mice fed a choline-deficient or high-fat diet. J Sci Food Agric. 2019;99(5):2602-9. [Crossref]  [PubMed] 
  66. Choi MS, Lee MK, Jung UJ, Kim HJ, Do GM, Park YB, et al. Metabolic response of soy pinitol on lipid-lowering, antioxidant and hepatoprotective action in hamsters fed-high fat and high cholesterol diet. Mol Nutr Food Res. 2009;53(6):751-9. [Crossref]  [PubMed] 
  67. Nassiri-Asl M, Zamansoltani F, Abbasi E, Daneshi MM, Zangivand AA. Effects of Urtica dioica extract on lipid profile in hypercholesterolemic rats. Zhong Xi Yi Jie He Xue Bao. 2009;7(5):428-33. [Crossref]  [PubMed] 
  68. Madduma Hewage S, Prashar S, O K, Siow YL. Lingonberry improves non-alcoholic fatty liver disease by reducing hepatic lipid accumulation, oxidative stress and inflammatory response. Antioxidants (Basel). 2021;10(4):565. [Crossref]  [PubMed]  [PMC] 
  69. Park HJ, Jung UJ, Lee MK, Cho SJ, Jung HK, Hong JH, et al. Modulation of lipid metabolism by polyphenol-rich grape skin extract improves liver steatosis and adiposity in high fat fed mice. Mol Nutr Food Res. 2013;57(2):360-4. [Crossref]  [PubMed] 
  70. Sahebkar A. Potential efficacy of ginger as a natural supplement for nonalcoholic fatty liver disease. World J Gastroenterol. 2011;17(2):271-2. [Crossref]  [PubMed]  [PMC] 

.: Up To Date

Login



Contact


Ortadoğu Reklam Tanıtım Yayıncılık Turizm Eğitim İnşaat Sanayi ve Ticaret A.Ş.

.: Address

Turkocagi Caddesi No:30 06520 Balgat / ANKARA
Phone: +90 312 286 56 56
Fax: +90 312 220 04 70
E-mail: info@turkiyeklinikleri.com

.: Manuscript Editing Department

Phone: +90 312 286 56 56/ 2
E-mail: yaziisleri@turkiyeklinikleri.com

.: English Language Redaction

Phone: +90 312 286 56 56/ 145
E-mail: tkyayindestek@turkiyeklinikleri.com

.: Marketing Sales-Project Department

Phone: +90 312 286 56 56/ 142
E-mail: reklam@turkiyeklinikleri.com

.: Subscription and Public Relations Department

Phone: +90 312 286 56 56/ 118
E-mail: abone@turkiyeklinikleri.com

.: Customer Services

Phone: +90 312 286 56 56/ 118
E-mail: satisdestek@turkiyeklinikleri.com

1. TERMS OF USE

1.1. To use the web pages with http://www.turkiyeklinikleri.com domain name or the websites reached through the sub domain names attached to the domain name (They will be collectively referred as "SITE"), please read the conditions below. If you do not accept these terms, please cease to use the "SITE." "SITE" owner reserves the right to change the information on the website, forms, contents, the "SITE," "SITE" terms of use anytime they want.

1.2. The owner of the "SITE" is Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. (From now on it is going to be referred as "Turkiye Klinikleri", shortly) and it resides at Turkocagi cad. No:30, 06520 Balgat Ankara. The services in the "SITE" are provided by "Turkiye Klinikleri."

1.3. Anyone accessing the "SITE" with or without a fee whether they are a natural person or a legal identity is considered to agree these terms of use. In this contract hereby, "Turkiye Klinikleri" may change the stated terms anytime. These changes will be published in the "SITE" periodically and they will be valid when they are published. Any natural person or legal identity benefiting from and reaching to the "SITE" are considered to be agreed to any change on hereby contract terms done by "Turkiye Klinikleri."

1.4. The "Terms of Use" hereby is published in the website with the last change on March 30th 2014 and the "SITE" is activated by enabling the access to everyone. The "Terms of Use" hereby is also a part of the any "USER Contract" was and/or will be done with the users using "Turkiye Klinikleri" services with or without a fee an inseparable.

2. DEFINITIONS

2.1. "SITE": A website offering different kind of services and context with a certain frame determined by "Turkiye Klinikleri" and it is accessible on-line on http://www.turkiyeklinikleri.com domain name and/or subdomains connected to the domain name.

2.2. USER: A natural person or a legal identity accessing to the "SITE" through online settings.

2.3. LINK: A link enabling to access to another website through the "SITE", the files, the context or through another website to the "SITE", the files and the context.

2.4. CONTEXT: Any visual, literary and auditory images published in the "Turkiye Klinikleri", "SITE" and/or any website or any accessible information, file, picture, number/figures, price, etc.

2.5. "USER CONTRACT": An electronically signed contract between a natural or a legal identity benefiting from special services "Turkiye Klinikleri" will provide and "Turkiye Klinikleri".

3. SCOPE OF THE SERVICES

3.1. "Turkiye Klinikleri" is completely free to determine the scope and quality of the services via the "SITE".

3.2. To benefit the services of "Turkiye Klinikleri" "SITE", the "USER" must deliver the features that will be specified by "Turkiye Klinikleri". "Turkiye Klinikleri" may change this necessity any time single-sided.

3.3. Not for a limited number, the services "Turkiye Klinikleri" will provide through the "SITE" for a certain price or for free are;

- Providing scientific articles, books and informative publications for health industry.

- Providing structural, statistical and editorial support to article preparation stage for scientific journals.

4. GENERAL PROVISIONS

4.1. "Turkiye Klinikleri" is completely free to determine which of the services and contents provided in the "SITE" will be charged.

4.2. People benefiting from the services provided by "Turkiye Klinikleri" and using the website can use the "SITE" only according to the law and only for personal reasons. Users have the criminal and civil liability for every process and action they take in the "SITE". Every USER agrees, declares and undertakes that they will not proceed by any function or action infringement of rights of "Turkiye Klinikleri"s and/or other third parties', they are the exclusive right holder on usage, processing, storage, made public and revealing any written, visual or auditory information reported to Turkiye Klinikleri" and/or "SITE" to the third parties. "USER" agrees and undertakes that s/he will not duplicate, copy, distribute, process, the pictures, text, visual and auditory images, video clips, files, databases, catalogs and lists within the "SITE", s/he will not be using these actions or with other ways to compete with "Turkiye Klinikleri", directly or indirectly.

4.3. The services provided and the context published within the "SITE" by third parties is not under the responsibility of "Turkiye Klinikleri", institutions collaborated with "Turkiye Klinikleri", "Turkiye Klinikleri" employee and directors, "Turkiye Klinikleri" authorized salespeople. Commitment to accuracy and legality of the published information, context, visual and auditory images provided by any third party are under the full responsibility of the third party. "Turkiye Klinikleri" does not promise and guarantee the safety, accuracy and legality of the services and context provided by a third party.

4.4. "USER"s cannot act against "Turkiye Klinikleri", other "USER"s and third parties by using the "SITE". "Turkiye Klinikleri" has no direct and/or indirect responsibility for any damage a third party suffered or will suffer regarding "USER"s actions on the "SITE" against the rules of the hereby "Terms of Use" and the law.

4.5. "USER"s accept and undertake that the information and context they provided to the "SITE" are accurate and legal. "Turkiye Klinikleri" is not liable and responsible for promising and guaranteeing the verification of the information and context transmitted to "Turkiye Klinikleri" by the "USER"s, or uploaded, changed and provided through the "SITE" by them and whether these information are safe, accurate and legal.

4.6. "USER"s agree and undertake that they will not perform any action leading to unfair competition, weakening the personal and commercial credit of "Turkiye Klinikleri" and a third party,  encroaching and attacking on personal rights within the "SITE" in accordance with the Turkish Commercial Code Law.

4.7. "Turkiye Klinikleri" reserves the right to change the services and the context within the "SITE"  anytime. "Turkiye Klinikleri" may use this right without any notification and timelessly. "USER"s have to make the changes and/or corrections "Turkiye Klinikleri" required immediately. Any changes and/or corrections that are required by "Turkiye Klinikleri", may be made by "Turkiye Klinikleri" when needed. Any harm, criminal and civil liability resulted or will result from changes and/or corrections required by "Turkiye Klinikleri" and were not made on time by the "USER"s belongs completely to the users.

4.8. "Turkiye Klinikleri" may give links through the "SITE" to other websites and/or "CONTEXT"s and/or folders that are outside of their control and owned and run by third parties. These links are provided for ease of reference only and do not hold qualification for support the respective web SITE or the admin or declaration or guarantee for the information inside. "Turkiye Klinikleri" does not hold any responsibility over the web-sites connected through the links on the "SITE", folders and context, the services or products on the websites provided through these links or their context.

4.9. "Turkiye Klinikleri" may use the information provided to them by the "USERS" through the "SITE" in line with the terms of the "PRIVACY POLICY" and "USER CONTRACT". It may process the information or classify and save them on a database. "Turkiye Klinikleri" may also use the USER's or visitor's identity, address, e-mail address, phone number, IP number, which sections of the "SITE" they visited, domain type, browser type, date and time information to provide statistical evaluation and customized services.

5. PROPRIETARY RIGHTS

5.1. The information accessed through this "SITE" or provided by the users legally and all the elements (including but not limited to design, text, image, html code and other codes) of the "SITE" (all of them will be called as studies tied to "Turkiye Klinikleri"s copyrights) belongs to "Turkiye Klinikleri". Users do not have the right to resell, process, share, distribute, display or give someone permission to access or to use the "Turkiye Klinikleri" services, "Turkiye Klinikleri" information and the products under copyright protection by "Turkiye Klinikleri". Within hereby "Terms of Use" unless explicitly permitted by "Turkiye Klinikleri" nobody can reproduce, process, distribute or produce or prepare any study from those under "Turkiye Klinikleri" copyright protection.

5.2. Within hereby "Terms of Use", "Turkiye Klinikleri" reserves the rights for "Turkiye Klinikleri" services, "Turkiye Klinikleri" information, the products associated with "Turkiye Klinikleri" copyrights, "Turkiye Klinikleri" trademarks, "Turkiye Klinikleri" trade looks or its all rights for other entity and information it has through this website unless it is explicitly authorized by "Turkiye Klinikleri".

6. CHANGES IN THE TERMS OF USE

"Turkiye Klinikleri" in its sole discretion may change the hereby "Terms of Use" anytime announcing within the "SITE". The changed terms of the hereby "Terms of Use" will become valid when they are announced. Hereby "Terms of Use" cannot be changed by unilateral declarations of users.

7. FORCE MAJEURE

"Turkiye Klinikleri" is not responsible for executing late or never of this hereby "Terms of Use", privacy policy and "USER Contract" in any situation legally taken into account as force majeure. Being late or failure of performance or non-defaulting of this and similar cases like this will not be the case from the viewpoint of "Turkiye Klinikleri", and "Turkiye Klinikleri" will not have any damage liability for these situations. "Force majeure" term will be regarded as outside of the concerned party's reasonable control and any situation that "Turkiye Klinikleri" cannot prevent even though it shows due diligence. Also, force majeure situations include but not limited to natural disasters, rebellion, war, strike, communication problems, infrastructure and internet failure, power cut and bad weather conditions.

8. LAW AND AUTHORISATION TO FOLLOW

Turkish Law will be applied in practicing, interpreting the hereby "Terms of Use" and managing the emerging legal relationships within this "Terms of Use" in case of finding element of foreignness, except for the rules of Turkish conflict of laws. Ankara Courts and Enforcement Offices are entitled in any controversy happened or may happen due to hereby contract.

9. CLOSING AND AGREEMENT

Hereby "Terms of Use" come into force when announced in the "SITE" by "Turkiye Klinikleri". The users are regarded to agree to hereby contract terms by using the "SITE". "Turkiye Klinikleri" may change the contract terms and the changes will be come into force by specifying the version number and the date of change on time it is published in the "SITE".

 

30.03.2014

Privacy Policy

We recommend you to read the terms of use below before you visit our website. In case you agree these terms, following our rules will be to your favor. Please read our Terms of Use thoroughly.

www.turkiyeklinikleri.com website belongs to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. and is designed in order to inform physicians in the field of health

www.turkiyeklinikleri.com cannot reach to user’s identity, address, service providers or other information. The users may send this information to the website through forms if they would like to. However, www.turkiyeklinikleri.com may collect your hardware and software information. The information consists of your IP address, browser type, operating system, domain name, access time, and related websites. www.turkiyeklinikleri.com cannot sell the provided user information (your name, e-mail address, home and work address, phone number) to the third parties, publish it publicly, or keep it in the website. Gathered information has a directing feature to be a source for the website’s visitor profile, reporting and promotion of the services.

www.turkiyeklinikleri.com uses the taken information:

-To enhance, improve and maintain the quality of the website

-To generate visitor’s profile and statistical data

-To determine the tendency of the visitors on using our website

-To send print publications/correspondences

-To send press releases or notifications through e-mail

-To generate a list for an event or competition

By using www.turkiyeklinikleri.com you are considered to agree that;

-Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. cannot be hold responsible for any user’s illegal and immoral behavior,

-Terms of use may change from time to time,

-It is not responsible for other websites’ contents it cannot control or the harms they may cause although it uses the connection they provided.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. may block the website to users in the following events:

-Information with wrong, incomplete, deceiving or immoral expressions is recorded to the website,

-Proclamation, advertisement, announcement, libelous expressions are used against natural person or legal identity,

-During various attacks to the website,

-Disruption of the website because of a virus.

Written, visual and audible materials of the website, including the code and the software are under protection by legal legislation.

Without the written consent of Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. the information on the website cannot be downloaded, changed, reproduced, copied, republished, posted or distributed.

All rights of the software and the design of the website belong to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. will be pleased to hear your comments about our terms of use. Please share the subjects you think may enrich our website or if there is any problem regarding our website.

info@turkiyeklinikleri.com